Open AccessNew treatment options of chronic urticaria
Author(s) -
Bernadett Hídvégi,
AUTHOR_ID,
Lilla Mihályi
Publication year - 2021
Publication title -
bőrgyógyászati és venerológiai szemle
Language(s) - English
Resource type - Journals
eISSN - 2064-261X
pISSN - 0006-7768
DOI - 10.7188/bvsz.2021.97.5.5
Subject(s) - omalizumab , chronic urticaria , medicine , intensive care medicine , disease , quality of life (healthcare) , chronic disease , dermatology , immunology , immunoglobulin e , nursing , antibody
Chronic urticaria is a multifactorial disease with increasing prevalence, that significantly deteriorates the quality of life of patients. Authors describe the pathomechanism of the disease, and they present the currently available treatment options and the promising future therapies as well. The therapeutic basis of chronic urticaria is the modern, 2nd generation antihistamines in a dosage of even four times higher than the regular one. In therapy resistant cases omalizumab or cyclosporin is advised. There is a growing demand for new medications because the number of those patients , who are non-responders or do not respond adequately to these therapies, is definitely increasing.